JP2025503322A5 - - Google Patents

Info

Publication number
JP2025503322A5
JP2025503322A5 JP2024565245A JP2024565245A JP2025503322A5 JP 2025503322 A5 JP2025503322 A5 JP 2025503322A5 JP 2024565245 A JP2024565245 A JP 2024565245A JP 2024565245 A JP2024565245 A JP 2024565245A JP 2025503322 A5 JP2025503322 A5 JP 2025503322A5
Authority
JP
Japan
Prior art keywords
antibody
seq
pharmaceutically acceptable
sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024565245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/072657 external-priority patent/WO2023143263A1/zh
Publication of JP2025503322A publication Critical patent/JP2025503322A/ja
Publication of JP2025503322A5 publication Critical patent/JP2025503322A5/ja
Pending legal-status Critical Current

Links

JP2024565245A 2022-01-25 2023-01-17 Ｈｅｒ３に対する抗体、複合体、及びその使用 Pending JP2025503322A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210089838 2022-01-25
CN202210089838.7 2022-01-25
PCT/CN2023/072657 WO2023143263A1 (zh) 2022-01-25 2023-01-17 一种针对Her3的抗体，偶联物及其用途

Publications (2)

Publication Number Publication Date
JP2025503322A JP2025503322A (ja) 2025-01-30
JP2025503322A5 true JP2025503322A5 (https=) 2026-01-26

Family

ID=87470655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024565245A Pending JP2025503322A (ja) 2022-01-25 2023-01-17 Ｈｅｒ３に対する抗体、複合体、及びその使用

Country Status (11)

Country Link
EP (1) EP4471063A1 (https=)
JP (1) JP2025503322A (https=)
KR (1) KR20240137076A (https=)
CN (1) CN118891283A (https=)
AU (1) AU2023210897A1 (https=)
CA (1) CA3243294A1 (https=)
IL (1) IL314470A (https=)
MX (1) MX2024009174A (https=)
TW (1) TW202334206A (https=)
WO (1) WO2023143263A1 (https=)
ZA (1) ZA202406384B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
CN121127474A (zh) * 2023-04-07 2025-12-12 信达生物制药(苏州)有限公司 喜树碱衍生物的抗体-药物偶联物以及其用途
WO2024208314A1 (zh) * 2023-04-07 2024-10-10 长春金赛药业有限责任公司 喜树碱衍生物、药物组合物及其制备方法和应用
EP4721766A1 (en) 2023-06-02 2026-04-08 Daiichi Sankyo Company, Limited Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
WO2025040012A1 (zh) * 2023-08-18 2025-02-27 康诺亚生物医药科技（成都）有限公司 五环类活性化合物及其偶联物和用途
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
CN120437319A (zh) * 2024-02-07 2025-08-08 长春金赛药业有限责任公司 带有连接系统的抗体药物偶联物
WO2025248072A1 (en) * 2024-05-30 2025-12-04 BioNTech SE Use of anti-her3 antibody-drug conjugates in cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA2813796C (en) 2010-10-18 2019-01-15 Mediapharma S.R.L. Erbb3 binding antibody
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
KR102445502B1 (ko) * 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP3091033A1 (en) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
CN117982673A (zh) * 2017-02-28 2024-05-07 第一三共株式会社 抗her3抗体-药物偶联物的应用
BR112020020466A2 (pt) 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
CN113135995B (zh) * 2020-01-17 2022-08-12 上海生物制品研究所有限责任公司 抗her3单克隆抗体及其应用

Similar Documents

Publication Publication Date Title
JP2025503322A5 (https=)
JP2024508081A5 (https=)
CN112543771B (zh) 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
TWI888610B (zh) 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途
JP2022515318A5 (https=)
CN104341504B (zh) 双特异性抗体
JP2021020956A (ja) 抗体−薬物コンジュゲートの選択的製造方法
JP6914956B2 (ja) 抗５ｔ４抗体および抗体−薬物コンジュゲート
CA3199566A1 (en) Anti-cd276 antibody, antibody-drug conjugate, and use thereof
CN116999572A (zh) 抗体－药物偶联物、药物组合物及其在制备治疗肿瘤的药物中的应用
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
EP3442574A1 (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
TW202537975A (zh) 抗體－藥物結合物之製造方法
JP2014531201A5 (https=)
JP2024544520A5 (https=)
JP7827624B2 (ja) 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途
CN116948035A (zh) 多特异性抗体及其制备和使用方法
JP2025508009A5 (https=)
JP2022506761A5 (https=)
WO2022063819A1 (en) Novel human antibodies binding to human cd3 epsilon
EP4374879A1 (en) Drug conjugate of eribulin derivative
WO2024230678A1 (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
JP2024508597A5 (https=)
JP2025511002A5 (https=)
WO2025056748A1 (en) Antibody-drug conjugate